AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01785186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 400mg
Study NCT01785186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid
Description: isoniazid 75 mg
Study NCT01785186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid
Description: isoniazid 75 mg
Study NCT01785186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: pyrazinamide 400 mg
Study NCT03261778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acromion 2.0 Brace
Description: Acromion 2.0 Brace will be worn for 6 weeks instead of the conventional Mitella sling
Study NCT03261778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acromion 2.0 Brace
Description: Acromion 2.0 Brace will be worn for 6 weeks instead of the conventional Mitella sling
Study NCT01785186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyrazinamide
Description: pyrazinamide 400 mg
Study NCT01785186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethambutol
Description: ethambutol 275 mg
Study NCT01812837 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Blue light
Description: Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
Study NCT01785186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethambutol
Description: ethambutol 275 mg
Study NCT01785186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pyridoxine
Description: pyridoxine 25 mg
Study NCT02569125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 4.5 mg/m² daily
Study NCT02494869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonlinear Aerobic Training
Study NCT01785186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pyridoxine
Description: pyridoxine 25 mg
Study NCT01537549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid and L-acetyl carnitine
Description: alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months
Study NCT03295539 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 'Indigo' Mechanical thrombectomy system
Description: Removal of acute clot from the artery causing ischaemia, using the mechanical aspiration system by Penumbra Inc called INDIGO
Study NCT02108613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Sessions
Description: 8 weeks of weekly exercise classes taught by a certified exercise physiologist.
Study NCT02108613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.
Study NCT02108613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support Volunteer
Description: Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.
Study NCT04317963 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bezlotoxumab
Description: Bezlotoxumab 10 mg/kg IV infusion in addition to standard CDI treatment
Study NCT04317963 — intervention group
Intervention type: DRUG
Intervention: Standard CDI treatment
Description: Standard CDI treatment includes one or a combination of oral vancomycin, oral vancomycin taper and/or pulse, fidaxomicin, and fidaxomicin taper and/or pulse
Study NCT02494869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Height, Weight, BMI measure
Study NCT02494869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Study NCT02494869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Study NCT02567435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV and PO
Study NCT01462500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.
Study NCT01483222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QUIKDRAW Pro, Aspen Medical Products
Description: Wearing an inelastic lumbar support (QUIKDRAW Pro, Aspen Medical Products) for 6 months
Study NCT01483222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUELLER 4581, Mueller Sports Medicine
Description: Wearing an elastic lumbar support (MUELLER 4581, Mueller Sports Medicine) for 6 months
Study NCT03101293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 film-coated tablet.
Study NCT03317145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrostimulation (NMES) device
Description: A mobile peroneal nerve stimulator
Study NCT03317145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent pneumatic compression (IPC) device
Description: A foot pump or foot compression device
Study NCT03281434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen peptide
Description: Low leucine content protein supplement to be consumed twice daily
Study NCT02567435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV
Study NCT02567435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT03281434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: High quality protein (DIAAS score), high leucine supplement, to be consumed twice daily
Study NCT02425865 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GOLIMUMAB
Description: Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
Study NCT01208922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin SV-MMX®
Description: 2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.
Study NCT01208922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: 1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.
Study NCT03150030 — intervention group
Intervention type: OTHER
Intervention: Combined hyper- and hypoglycaemic clamp
Description: During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.
Study NCT03150030 — intervention group
Intervention type: DEVICE
Intervention: Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)
Description: Implantation of a loop-recorder
Study NCT03150030 — intervention group
Intervention type: DEVICE
Intervention: Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)
Description: Monitoring with a continuous glucose monitor
Study NCT03271463 — intervention group
Intervention type: BEHAVIORAL
Intervention: Selective Control Assessment of Lower Extremity (SCALE)
Description: Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
Study NCT01270841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule 1x daily for 3 months
Study NCT02567435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02567435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01270841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical testosterone
Description: testosterone gel applied 1x daily for 3 months
Study NCT01270841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
Study NCT01462695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01462695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01462695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT00875368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maraviroc
Description: maraviroc dose dependent on co-medication
Study NCT00875368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study NCT04098549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid lowering of plasma glucose
Description: Rapid lowering of plasma glucose using hypoglycemic clamp technique
Study NCT04098549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow lowering of plasma glucose
Description: Slow lowering of plasma glucose using hypoglycemic clamp technique
Study NCT02067715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tooth bleaching
Description: The bleaching agent will be used in a single-application of 45 minutes.
Study NCT02067715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tooth bleaching
Description: The bleaching agent will be used in a single-application of 45 minutes.
Study NCT02535052 — intervention group
Intervention type: BIOLOGICAL
Intervention: Seasonal influenza and pneumococcal polysaccharide vaccines
Description: Vaccination
Study NCT01400854 — intervention group
Intervention type: DRUG
Intervention: Effentora®
Description: prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
Study NCT05737888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI Neurofeedback
Description: 15 intervention sessions on a 3T MRI scanner.
Study NCT05737888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG Neurofeedback
Description: 15 intervention sessions with a standard EEG-cap with 64 active electrodes.
Study NCT05737888 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: 10 intervention sessions of CBT group therapy, as per local university hospital standard of care.
Study NCT02400905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioMimics 3D Vascular Stent System
Description: Femoropopliteal stenting
Study NCT02194166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV or SC will be administered as described.
Study NCT02194166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered in accordance with local hospital practice.
Study NCT02194166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered in accordance with local hospital practice.
Study NCT02867020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
Study NCT02867020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
Study NCT02867020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
Study NCT02867020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
Study NCT02867020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
Study NCT02867020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Subjects will receive prednisone 10mg/day.
Study NCT03707483 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: combination of vitamin C and platelet rich fibrin
Description: combination of vitamin C and platelet rich fibrin
Study NCT03707483 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: combination of vitamin C and platelet rich fibrin
Description: combination of vitamin C and platelet rich fibrin
Study NCT00897442 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01434706 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nucleic Acid Amplification Testing
Description: The Gen-Probe Transcription-Mediated Amplification (TMA) technology exponentially amplifies captured HIV-1 and HCV RNA in blood samples. The Gen-Probe system is available in two commercially available FDA approved products; 1) the Procleix assay is a multiplex system that is used to screen the blood supply for HIV and HCV. This assay will allow the simultaneous detection of all known HIV-1 subtypes with sensitivities designed to reduce the window period of false negative results from standard HIV antibody testing (EIA), while maintaining the ability to discriminate positive from negative specimens, even at very low copy numbers (Giachetti, Linnen et al., 2002).
Study NCT02289924 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Administration by intravitreal injection
Study NCT06180967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Syrup
Description: Administered Orally.
Study NCT06180967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Solution
Description: Administered IV bolus.
Study NCT06180967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered Orally.
Study NCT04221087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Sugar water based on same ml dosing of intervention arm drug
Study NCT04221087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: 0.6mg/kg/dose - single oral dose administration to intervention arm
Study NCT03016078 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mepilex Border Post-Op Ag
Description: To investigate if there was any skin damage under the dressing from operation day to last visit.
Study NCT02659267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions Group
Description: VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
Study NCT02678897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxynorm on-demand
Description: We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5.
Study NCT02678897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxynorm via PCA
Description: We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~1. If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~2. Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5.
Study NCT01823484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AN 69 ST hemofilter
Study NCT01823484 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AN 69 hemofilter
Study NCT02494869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test
Study NCT03114605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Study NCT01750775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shensong Yangxin capsule
Description: ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks
Study NCT02611999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single median price information
Description: Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
Study NCT02611999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paired inside/outside price information
Description: Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
Study NCT02032290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of Coronary Flow Reserve
Study NCT02032290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Study NCT02032290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor loading
Study NCT02032290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel loading
Study NCT04377178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dentin grinder
Description: After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - dentin grinder from the separated root and these particles are incorporated into the extraction socket
Study NCT04377178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone mill
Description: After atraumatic extraction of the tooth, autogenous dentin particles are made with the help of a device - Bone mill from the separated root and these particles are incorporated into the extraction socket
Study NCT03473470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: forced air warming and warmed intravenous fluids
Description: Use of warming system (forced air)
Study NCT03473470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: warmed intravenous fluids
Description: Use of warming system to have warmed intravenous fluids
Study NCT03213561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stable and Independent Brain-computer Interfaces for Communication
Description: The participants will perform an MRI head scan, which the investigators will use to construct 3D head models of participants. The investigators will use these modele to reconstruct the activity of brain sources from EEG signals. The participants will then take part in a series of EEG recording sessions. During the initial calibration sessions, the participants will react with real or attempted movements to visual cues. The investigators will use the EEG signals from these sessions to calibrate the text-entry interface used in the validation sessions that follow. During the validation sessions, the participants will control the text-entry interface to write messages using their EEG signals.
Study NCT03627195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-1349M
Description: DSP-1349M injectable
Study NCT03627195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo injection